◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › N › NVAX

Novavax Inc (NVAX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-15

Novavax Inc (NVAX) operates in the BIOTECHNOLOGY industry and is headquartered in Gaithersburg, United States with about 749 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, NVAX reported $1.1B in revenue and $440M in net income.

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.

Interactive charts & full statements → Open the NVAX valuation workbench →

NVAX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$414M	$1.1B	$682M	$556M	$1.6B	$1.1B	$476M	$19M	$34M	$31M	$15M	$36M	$31M	$21M	$22M	$15M	$0M	$0M	$1M	$2M	$5M
Gross Profit	$322M	$1.1B	$479M	$213M	$696M	$1.1B	$476M	($95M)	$34M	$31M	($223M)	($126M)	$16M	$13M	$7M	$8M	$0M	$0M	$1M	$1M	($2M)
Gross Margin %	77.8%	93.7%	70.3%	38.2%	43.5%	100.0%	100.0%	-510.0%	100.0%	100.0%	-1449.8%	-348.7%	51.1%	60.7%	33.5%	52.3%	100.0%	100.0%	100.0%	85.4%	-38.2%
Operating Income (EBIT)	($227M)	$563M	($249M)	($567M)	($645M)	($1.7B)	($417M)	($121M)	($174M)	($172M)	($269M)	($157M)	($84M)	($52M)	($30M)	($22M)	($38M)	($37M)	($34M)	($30M)	($25M)
Operating Margin %	-54.9%	50.1%	-36.5%	-101.8%	-40.3%	-147.1%	-87.6%	-646.1%	-507.2%	-550.8%	-1752.8%	-433.8%	-273.0%	-250.7%	-134.4%	-146.9%	-11222.7%	-11502.5%	-3229.3%	-2000.7%	-525.5%
Net Income	($248M)	$440M	($187M)	($545M)	($658M)	($1.7B)	($428M)	($130M)	($185M)	($184M)	($280M)	($157M)	($83M)	($52M)	($29M)	($19M)	($36M)	($38M)	($36M)	($35M)	($23M)
Net Margin %	-59.9%	39.2%	-27.5%	-98.0%	-41.1%	-152.1%	-89.9%	-697.1%	-538.8%	-589.5%	-1823.5%	-432.9%	-270.5%	-248.5%	-129.1%	-131.8%	-10410.5%	-11807.4%	-3388.1%	-2297.8%	-492.6%
EBITDA	($203M)	$492M	($108M)	($487M)	($605M)	($1.7B)	($412M)	($113M)	($166M)	($162M)	($261M)	($151M)	($78M)	($49M)	($27M)	($17M)	($36M)	($38M)	($34M)	($31M)	($18M)
Earnings Per Share (EPS)	$-1.53	$2.54	$-1.23	$-5.41	$-8.42	$-23.44	$-7.43	$-5.40	$-9.99	$-12.56	$-20.68	$-11.97	$-7.35	$-6.13	$-4.33	$-3.41	$-6.82	$-8.97	$-10.58	$-11.38	$-7.86
Shares Outstanding (M)	165M	173M	152M	101M	78M	74M	58M	24M	18M	15M	14M	13M	11M	8M	7M	6M	5M	4M	3M	3M	3M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NVAX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$57M	$140M	$147M	$70M	$239M	$667M	$88M	$85M
Gross Profit	$42M	$109M	$122M	$49M	$225M	$653M	$52M	$24M
Gross Margin %	74.9%	78.0%	82.9%	69.5%	94.0%	97.9%	58.5%	28.3%
Operating Income (EBIT)	($55M)	($15M)	$21M	($178M)	$106M	$516M	($131M)	($134M)
Operating Margin %	-96.8%	-11.1%	14.3%	-252.7%	44.2%	77.3%	-148.4%	-158.6%
Net Income	($53M)	($9M)	$18M	($202M)	$107M	$519M	($81M)	($121M)
Net Margin %	-94.2%	-6.8%	11.9%	-287.3%	44.5%	77.8%	-91.8%	-143.5%
EBITDA	($40M)	($1M)	$29M	($191M)	$121M	$534M	($53M)	($105M)
Earnings Per Share (EPS)	$-0.32	$-0.06	$0.10	$-1.25	$0.60	$2.92	$-0.51	$-0.76
Shares Outstanding (M)	165M	163M	173M	162M	177M	178M	160M	160M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NVAX Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($39M)	($245M)	($87M)	($714M)	($416M)	$323M	($43M)	($137M)	($185M)	($139M)	($255M)	($126M)	($67M)	($45M)	($18M)	($24M)	($33M)	($33M)	($24M)	($27M)	($15M)
Capital Expenditures (CapEx)	$7M	$6M	$13M	$59M	$93M	$57M	$55M	$2M	$1M	$4M	$18M	$18M	$7M	$6M	$4M	$1M	$2M	$1M	$6M	$2M	$2M
Free Cash Flow (FCF)	($46M)	($250M)	($100M)	($773M)	($509M)	$265M	($97M)	($138M)	($186M)	($143M)	($274M)	($144M)	($74M)	($51M)	($23M)	($24M)	($34M)	($34M)	($30M)	($29M)	($16M)
FCF Margin %	-11.2%	-22.3%	-14.7%	-138.9%	-31.8%	23.2%	-20.4%	-742.0%	-543.0%	-458.3%	-1782.6%	-398.3%	-242.3%	-244.5%	-102.2%	-165.0%	-10031.5%	-10330.8%	-2819.5%	-1897.1%	-348.6%
Dividends Paid	—	—	—	—	—	—	$39M	—	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NVAX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($75M)	($32M)	($39M)	$108M	($127M)	($186M)	($173M)	($145M)
Capital Expenditures (CapEx)	$1M	$1M	$2M	$2M	$0M	$2M	$2M	$2M
Free Cash Flow (FCF)	($77M)	($34M)	($42M)	$106M	($128M)	($187M)	($175M)	($147M)
FCF Margin %	-135.2%	-24.1%	-28.2%	150.2%	-53.4%	-28.1%	-198.6%	-173.7%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NVAX Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$956M	$1.2B	$1.6B	$1.8B	$2.3B	$2.6B	$1.6B	$173M	$208M	$302M	$394M	$386M	$276M	$236M	$102M	$67M	$75M	$86M	$77M	$91M	$122M
Cash & Cash Equivalents	$191M	$241M	$530M	$569M	$1.3B	$1.5B	$553M	$79M	$70M	$106M	$144M	$93M	$32M	$119M	$17M	$14M	$8M	$39M	$27M	$4M	$7M
Total Liabilities	$1.1B	$1.3B	$2.2B	$2.5B	$2.9B	$2.9B	$955M	$359M	$376M	$404M	$400M	$93M	$46M	$33M	$22M	$13M	$16M	$11M	$31M	$28M	$28M
Total Debt (Short + Long-Term)	$296M	$247M	$177M	$173M	$519M	$454M	$644M	$322M	$344M	$352M	$346M	$0M	$1M	$2M	$1M	$0M	$0M	$0M	$23M	$23M	$23M
Total Shareholders' Equity	($191M)	($128M)	($624M)	($717M)	($634M)	($352M)	$627M	($186M)	($168M)	($102M)	($6M)	$293M	$230M	$203M	$80M	$54M	$59M	$74M	$45M	$63M	$94M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NVAX viewer.

Other Companies in BIOTECHNOLOGY

VIR · Vir Biotechnology Inc — $2 billion
TYRA · Tyra Biosciences Inc — $2 billion
NTLA · Intellia Therapeutics Inc — $2 billion
NBTX · Nanobiotix — $2 billion
KLRA · Kailera Therapeutics, Inc. Common Stock — $2 billion
ABSI · Absci Corp — $2 billion
TSHA · Taysha Gene Therapies Inc — $2 billion
ANAB · AnaptysBio Inc — $2 billion

← NV All “N” companies NVBT →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.